News

Does Amgen (AMGN) Have Enough Cash Flow To Justify Its Price?

Amgen shares have surged over recent years and a stream of high profile clinical wins has kept the story in the spotlight, which raises a simple question for you as an investor. Do the company’s current cash flows and their projected path really support today’s valuation, or has sentiment moved faster than the underlying economics? Over the past 5 years, Amgen has delivered a 147.6% share price gain, so a lot of future cash generation is already being referenced by the market. New oncology...

Yahoo·19:24AMGN▲+0.7%

AMGEN APPOINTS DAVID W. GIBBS TO BOARD OF DIRECTORS

Amgen (NASDAQ: AMGN) today announced the appointment of David W. Gibbs to its Board of Directors, effective immediately. Gibbs will serve on the Board's Audit Committee and Compensation and Management Development Committee.

Yahoo·17:52AMGN▲+0.7%

ESMO ‘26: A cancer vaccine debate, Roche’s KRAS progress and Amgen’s ‘unprecedented’ data

At one of the year’s premiere meetings for cancer research, melanoma vaccine data hailed by scientists sparked a share sell-off on Wall Street, while a lung drug received a standing ovation.

Yahoo·11:58AMGN▲+0.7%

Committee stocks on the move: EQT Corporation, Amgen and Lockheed Martin

The Investment Committee discusses some stocks they own that are on the move.

CNBC·09:11AMGN▲+0.7%

Amgen, AstraZeneca Drug Combo Shows Promising Survival Results in Tough-To-Treat Lung Cancer

Amgen's Imdelltra with Imfinzi cut small-cell lung cancer death risk by 58% in Phase 3, extending median survival to 21.1 months. Read more.

Benzinga·05:23AMGN▲+0.7%

Amgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy?

Both of these biotech stocks could be appealing to income investors.

Yahoo·04:46AMGN▲+0.7%

Amgen Inc. (AMGN) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress Transcript

Amgen Inc. (AMGN) 2026 European Society for Medical Oncology (ESMO) Annual Congress October 24, 2026 2:30 PM EDTCompany ParticipantsCasey Capparelli -...

SeekingAlpha·15:17AMGN▲+0.7%

Amgen’s Imdelltra Cut Lung Cancer Deaths by 58%. Is It Already in the Stock?

Amgen (AMGN:NASDAQ) put numbers on its biggest lung cancer win yet on Saturday, Oct. 24.

Yahoo·14:21AMGN▲+0.7%

Amgen Inc. (AMGN) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress - Slideshow

2026-10-24. The following slide deck was published by Amgen Inc.

SeekingAlpha·12:30AMGN▲+0.7%

Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

A drug from Amgen could give patients with an aggressive form of lung cancer significantly more time to live when added to an immunotherapy from AstraZeneca.

CNBC·06:30AMGN▲+0.7%

Amgen (AMGN) Reports Positive Phase 3 TEZSPIRE Results In Eosinophilic Esophagitis

Amgen (NasdaqGS:AMGN) and AstraZeneca reported positive full Phase 3 results for TEZSPIRE in eosinophilic esophagitis (EoE). The Phase 3 trial showed significant and clinically meaningful improvements in EoE symptoms and endoscopic endpoints sustained through one year. Investigators reported a favorable safety profile for TEZSPIRE in this EoE study population of patients with limited treatment options. The TEZSPIRE Phase 3 EoE data lands alongside wider findings from our research on Amgen's...

Yahoo·22:14AMGN▲+0.7%

Here's Why Amgen (AMGN) Fell More Than Broader Market

Amgen (AMGN) closed at $439.26 in the latest trading session, marking a -1.79% move from the prior day.

Yahoo·16:50AMGN▲0.7%

Amgen vs. Eli Lilly: Does the GLP-1 Mania Make LLY Stock a Better Buy in 2026?

Amgen trades at half the valuation multiple of Eli Lilly while generating stronger free cash flow, but explosive growth in obesity drugs tells a different story.

Yahoo·18:15AMGN▲+0.7%

Amgen (AMGN) Gains As Market Dips: What You Should Know

Amgen (AMGN) closed at $447.28 in the latest trading session, marking a +2.04% move from the prior day.

Yahoo·17:00AMGN▲+0.7%

Amgen (AMGN) Sales Grew 10%, but Can Earnings Catch Up to the Price?

Amgen (NASDAQ:AMGN) and AstraZeneca reported Phase 3 results this week for Tezspire in eosinophilic esophagitis, a condition that makes swallowing difficult. The trial met both of its main goals, and the benefit lasted through week 52. Tezspire is approved for severe asthma, so a new use would widen a drug that is already growing fast. […]

Yahoo·13:30AMGN▲+0.7%

What Changed In Amgen's Story?

For questions about this article or underlying research, email help@trefis.com.

Yahoo·13:06AMGN▲+0.7%

Amgen and AstraZeneca report Phase III Tezspire data for EoE

The trial evaluated 368 participants aged 12 to 80 years who were permitted to continue stable background therapies.

Yahoo·06:43AMGN▲+0.7%

Barclays Maintains Equal-Weight on Amgen, Raises Price Target to $400

Barclays analyst Emily Field maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and raises the price target from $380 to $400.

Benzinga·04:53AMGN▲+0.7%

Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

Amgen boasts stronger revenue growth, while Bristol Myers Squibb generates nearly 60% more free cash flow at half the valuation.

Yahoo·18:05AMGN▲+0.7%

AMGEN TO PRESENT AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS 2026

Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Society of Medical Oncology Congress (ESMO) 2026 on Saturday, October 24, 2026 at 11:30 a.m. PT. Murdo Gordon, executive vice president of Global Markets and Policy at Amgen, and Jean-Charles Soria, senior vice president of oncology within Global Development at Amgen, as well as other members of Amgen's management team, will discuss Amgen's oncology portfolio and selected data being present

Yahoo·16:15AMGN0.7%

AstraZeneca/Amgen Drug Shows Significant Remission in Eosinophilic Esophagitis Study

AstraZeneca and Amgen report positive Phase 3 Tezspire data, showing sustained remission in eosinophilic esophagitis patients over 52 weeks.

Benzinga·08:51AMGN▲+0.7%

Amgen, AstraZeneca Announces Data From Phase 3 CROSSING Study Demonstrated TEZSPIRE Showed Histologic Remission For 64.8% For 210 Mg Dose At Week 24; TEZSPIRE Also Reduced Frequency, Severity Of Dysphagia Symptoms 18.8 Points

Amgen (NASDAQ:AMGN) and AstraZeneca today announced full results from the positive Phase 3 CROSSING trial that showed TEZSPIRE® (tezepelumab-ekko) demonstrated statistically significant and clinically meaningful

Benzinga·05:06AMGN0.7%

How Earnings Beat At Amgen Stock Has Changed Its Investment Story

Amgen recently reported a 10% rise in second quarter revenue, continued to beat earnings and sales estimates, and maintained a dividend yield of 2.5% with annual increases of 8% from 2020 to 2025. The combination of consistent estimate beats, modest upward earnings revisions and faster dividend growth than Merck signals a business leaning on disciplined capital returns as well as expanding newer therapies. We will look at how Amgen's investment narrative is influenced by sustained dividend...

Yahoo·23:23AMGN▲+0.7%

Merck vs. Amgen: Which Dividend Stock Pays You More in 10 Years?

Key TakeawaysMerck raised its 2026 sales outlook on Aug. 4, the same day Amgen reported second-quarter revenue up 10%.

Yahoo·17:39AMGN▲0.7%

Amgen Has the Drugs and the Dividend. Now It Needs the Growth

Amgen Inc. (NASDAQ:AMGN) has carved out a strong spot in the biotech world, thanks to its lineup of medicines for cancer, heart disease, inflammation, and some rare conditions. The company’s tried-and-true products bring in plenty of cash, and its newer treatments show real promise for growth. For those looking beyond a single pharmaceutical stock, the 10 […]

Yahoo·10:07AMGN▲+0.7%

Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know

Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Yahoo·08:00AMGN▲+0.7%

Amgen's Q3 2026 Earnings: What to Expect

Amgen is scheduled to report its third-quarter results next month, and analysts expect a single-digit earnings rise.

Yahoo·00:46AMGN▲+0.7%

When Amgen's Forecast And Chart Say The Same Thing, Pay Attention

Amgen (AMGN) raised its revenue forecast for fiscal 2026 on August 4. Since the market close before that release, the stock has gained 15.2%, outpacing the 1.9% return of the S&P 500. A higher forecast or a climbing share price means little in isolation. When the corporate numbers and the technical chart align, however, the combination warrants closer scrutiny. So how far did management raise its forecast, and why.

Yahoo·20:53AMGN▲+0.7%

Is Amgen Stock Increasing Your Market Risk?

Investors holding shares of Amgen (AMGN), the $234 billion maker of drugs such as Repatha and Prolia, likely pair that position with broad exposure to the S&P 500. As the broader market rises and falls each day, the pharmaceutical stock's individual performance blends with the rest of that capital. So when the market drops, does Amgen make your losses bigger.

Yahoo·20:13AMGN0.7%

Here's How Much $100 Invested In Amgen 15 Years Ago Would Be Worth Today

Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 1.45% on an annualized basis producing an average annual return of 14.3%. Currently, Amgen has a market capitalization of $230.37 billion.

Benzinga·07:30AMGN▲+0.7%

Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider

The latest trading day saw Amgen (AMGN) settling at $434.03, representing a +1.86% change from its previous close.

Yahoo·16:50AMGN▲+0.7%

AMGN vs. MRK: Which Pharma Giant’s Dividend Actually Has Room to Grow

Amgen and Merck both yield around 2.3% and have surged this year, but one of them is paying its dividend out of thin air while the other has a cash cushion that changes the entire income calculus.

Yahoo·12:45AMGN▲+0.7%

Amgen (AMGN) Gains Attention On Aging Treatments, Is The Upside Already Priced In?

Why Amgen Stock Is Back In Focus Amgen (AMGN) moved into the spotlight after its share price climbed sharply alongside growing attention on treatments for age related conditions in the U.S., putting its role in an aging society under closer investor scrutiny. Over the past few months, momentum around Amgen has picked up, with a 30 day share price return of 9.41% and a 90 day move of 15.22% helping lift the stock to US$412.84. The 1 year total shareholder return of 44.39% and 5 year total...

Yahoo·11:25AMGN▲+0.7%

What Could Amgen (AMGN) 70% Remission Trial Result Mean For Its Pipeline?

Amgen (NasdaqGS:AMGN) and AstraZeneca reported positive Phase 3 results for Tezspire in eosinophilic esophagitis on 14 October 2026. In the trial, nearly 70% of patients receiving the higher Tezspire dose achieved remission at week 24. The study targeted eosinophilic esophagitis, a chronic inflammatory condition that currently has limited approved treatment options. The Tezspire eosinophilic esophagitis Phase 3 success is only one part of the wider Amgen story investors may want to...

Yahoo

Is Amgen Stock Worth More Than Its Competitors?

Amgen (AMGN) competes in a tight peer group of six large drugmakers alongside AbbVie, Johnson & Johnson, Merck, Pfizer, and Bristol-Myers Squibb. The company ranks second within this group for both sales growth and operating margin. Its valuation tells a different story. Leaving out Merck and Pfizer, which each reported a loss in at least one of their last four quarters, Amgen has the third highest P/E of the four companies that can be compared. So how far apart are what Amgen delivers and what

Yahoo·19:48AMGN▲+0.7%

Guggenheim Maintains Neutral on Amgen, Lowers Price Target to $378

Guggenheim analyst Vamil Divan maintains Amgen (NASDAQ:AMGN) with a Neutral and lowers the price target from $388 to $378.

Benzinga·04:58AMGN▲0.7%

BMO Capital Maintains Market Perform on Amgen, Lowers Price Target to $415

BMO Capital analyst Evan David Seigerman maintains Amgen (NASDAQ:AMGN) with a Market Perform and lowers the price target from $450 to $415.

Benzinga·09:37AMGN▲+0.7%

Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?

One offers a more affordable entry point while the other boasts some of the highest profit margins in the sector. The choice comes down to whether you prioritize income stability or growth potential.

Yahoo·10:34AMGN▲+0.7%

Ohio Rep. David Taylor Bought Up to $45K Worth of Amgen Stock

October 1, 2026 records indicate that Representative David Taylor filed a purchase of Amgen (NASDAQ:AMGN), valued between $3,003 and $45,000. According to the October filing, the transaction occurred on September 22,

Benzinga·07:00AMGN▲+0.7%

Amgen (AMGN) Stock Dips While Market Gains: Key Facts

Amgen (AMGN) closed at $407.27 in the latest trading session, marking a -3.38% move from the prior day.

Yahoo·16:50AMGN▲+0.7%

Why Amgen’s 6% Dividend Raise Masks a Tougher Road Ahead

Amgen just handed income investors another dividend raise, but a mountain of acquisition debt, crumbling legacy drugs, and a billion-dollar obesity bet are all competing for the same pool of cash.

Yahoo·09:03AMGN▲+0.7%

Scotiabank Maintains Sector Outperform on Amgen, Raises Price Target to $500

Scotiabank analyst Louise Chen maintains Amgen (NASDAQ:AMGN) with a Sector Outperform and raises the price target from $450 to $500.

Benzinga·06:57AMGN▲+0.7%

Amgen (AMGN) Has a New Growth Opportunity. But How Much Is It Really Worth?

On September 22, Amgen Inc. (NASDAQ:AMGN) announced positive topline Phase 3 results for dazodalibep in systemic Sjögren’s disease. The trial met its primary endpoint, demonstrating statistically significant and clinically meaningful improvements in systemic disease activity. Following the announcement, Citi reaffirmed a Neutral rating and $405 price target on Amgen. While Citi noted that the results […]

Yahoo·21:27AMGN▲+0.7%

Amgen (AMGN), What Is Behind The Fresh Attention?

Amgen (AMGN) just reported positive topline data from its Phase 3 OASIZ 301 trial of dazodalibep in Sjögren's disease, an update that puts fresh attention on the stock's autoimmune pipeline potential. Set against that clinical update, Amgen’s share price has climbed 15.5% over the past 90 days and 27.6% year to date, while the 1-year total shareholder return of 56.9% and 5-year total shareholder return of 131.0% point to strong longer term momentum building around the story. Spot emerging...

Yahoo·20:08

Why Amgen’s Pipeline Just Got More Interesting

Amgen Inc. (NASDAQ:AMGN)’s experimental drug dazodalibep met the main goal of a late-stage trial for Sjögren’s disease. After 48 weeks, patients with moderate-to-severe disease activity showed statistically significant and clinically meaningful improvements. Most adverse events were mild to moderate, and only a small number of patients stopped treatment. Sjögren’s affects about 1% of the global […]

Yahoo·16:34AMGN▲+0.7%

Sector Update: Healthcare Stocks Rise Late Afternoon

Healthcare stocks rose late Tuesday afternoon, with the NYSE Healthcare Index adding 0.5% and the St

Yahoo·16:03

Amgen reports a Phase 3 win with Sjögren’s drug candidate

Dazodalibep, acquired in Amgen’s big buyout of Horizon Therapeutics, succeeded in the first of two late-stage trials against the tough-to-treat autoimmune disorder.

Yahoo·14:31AMGN▲+0.7%

AMGN Jumps After Win In Sjögren’s Disease Trial As Citi Flags ‘Open Questions’

In a trial in patients with Sjögren’s disease, Amgen’s dazodalibep produced a statistically significant and clinically meaningful improvement on a standard score of how the disease affects organs and systems.

Amgen (AMGN) Posted Positive Phase 3 Results In Sjögren's Disease

Amgen (NasdaqGS:AMGN) reported positive Phase 3 trial results for dazodalibep in Sjögren's disease, targeting a major unmet autoimmune need. The company described dazodalibep as a potential first-in-class therapy, following successful outcomes in patients with Sjögren's disease. Amgen received an FDA label update for IMDELLTRA in extensive-stage small cell lung cancer, reducing recommended patient monitoring times. The dazodalibep Phase 3 success and IMDELLTRA monitoring change both reshape...

Yahoo·13:13AMGN▲+0.7%

Amgen (AMGN) Stock Sees Modest Fair Value Lift As Analysts Weigh Pipeline Risks

Amgen’s updated analyst model now points to a fair value price target of US$388.03, compared with the prior US$371.93. This provides a slightly higher anchor for how the stock is being valued today. This shift comes as recent research highlights a split view, with some analysts focusing on strong commercial execution and others stressing that questions around patents and the pipeline may already be reflected in the share price. As you read on, you will see how to interpret these moving...

Yahoo·22:09AMGN▲+0.7%

Amgen (AMGN) Surpasses Market Returns: Some Facts Worth Knowing

In the most recent trading session, Amgen (AMGN) closed at $385.65, indicating a +1.55% shift from the previous trading day.

Yahoo·17:50AMGN▲0.7%

Top Research Reports for AMD, Linde & Amgen

AMD, Linde and Amgen highlight AI demand, contracted growth and drug launches, while supply, margin and pipeline risks remain key factors.

Yahoo·16:28AMGN▲+0.7%

Can Sotyktu's Long-Term PsA Data Boost Bristol Myers' Prospects?

Bristol Myers' Sotyktu delivers durable PsA responses for two years, supporting its growth strategy as competition intensifies.

Yahoo·15:17

A Failed Cholesterol Drug Raises the Stakes for Amgen (AMGN) and Eli Lilly (LLY) Too

On September 8, 2026, CNBC reported that Novartis’ failed pelacarsen trial has raised the stakes for rival experimental cholesterol drugs from Amgen Inc. (NASDAQ:AMGN) and Eli Lilly and Company (NYSE:LLY), both of which are racing to prove that lowering lipoprotein(a), or Lp(a). It can meaningfully reduce heart attacks and strokes. Analysts said Amgen’s olpasiran faces […]

Yahoo·19:57AMGN▲+0.7%

Amgen Inc. (AMGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Amgen Inc. (AMGN) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 11:30 AM EDTCompany ParticipantsThomas J.

SeekingAlpha·13:01AMGN▲+0.7%

4 Defensive Stocks to Take Refuge in as Consumer Sentiment Plummets

ADM, COCO, AMGN and CNC offer defensive exposure as inflation, oil prices and weak consumer sentiment fuel market volatility.

Yahoo·08:08AMGN▲+0.7%

Leading Biotech Selects Veeva Vault CRM Globally

Veeva Systems (NYSE: VEEV) today announced that Amgen plans to deploy Veeva Vault CRM globally, building on a collaboration spanning more than a decade.

Yahoo·07:03AMGN▲+0.7%

Is This LLY Stock Dip Big Enough To Be Worth Buying?

Eli Lilly (LLY) trades near $1,120, about 13% below the high it set in August, and the question is whether to step in. The stock's record after sharp falls is clean but short. That record asks for the better part of a year and more pain before it pays. And this fall is not the kind of fall that record is built on.

Yahoo·16:09